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Abstract
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced apoptosis specifically in tumor cells. However, with
approximately half of all known tumor lines being resistant to TRAIL, the identification of TRAIL sensitizers and their
mechanism of action become critical to broadly use TRAIL as a therapeutic agent. In this study, we explored whether c-Met
protein contributes to TRAIL sensitivity. We found a direct correlation between the c-Met expression level and TRAIL
resistance. We show that the knock down c-Met protein, but not inhibition, sensitized brain tumor cells to TRAIL-mediated
apoptosis by interrupting the interaction between c-Met and TRAIL cognate death receptor (DR) 5. This interruption greatly
induces the formation of death-inducing signaling complex (DISC) and subsequent downstream apoptosis signaling. Using
intracranially implanted brain tumor cells and stem cell (SC) lines engineered with different combinations of fluorescent and
bioluminescent proteins, we show that SC expressing a potent and secretable TRAIL (S-TRAIL) have a significant anti-tumor
effect in mice bearing c-Met knock down of TRAIL-resistant brain tumors. To our best knowledge, this is the first study that
demonstrates c-Met contributes to TRAIL sensitivity of brain tumor cells and has implications for developing effective
therapies for brain tumor patients.
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Introduction
c-Met, a transmembrane tyrosine kinase encoded by a c-met
proto-oncogene [1,2], has emerged as a key determinant of brain
tumor growth [3]. c-Met is expressed in a wide variety of brain
tumors, including glioblastoma multiforme (GBM) and medullo-
blastoma (MB), and its expression level frequently correlates with
tumors histological grade and poor patient prognosis [4].
Overexpression or abnormal activation of c-Met in tumor cells
leads to induction of proliferation, migration, and invasion along
with the inhibition of apoptosis. Conversely, downregulation of c-
Met in experimental human tumor xenografts leads to inhibition
of tumor growth [5]. Different approaches to inhibit c-Met and its
downstream signaling pathways have recently been developed,
including small molecular tyrosine kinase inhibitors [6], which are
currently undergoing clinical trials in cancer patients.
Tumor necrosis factor related apoptosis-inducing ligand
(TRAIL) is a pro-apoptotic protein that specifically targets tumor
cells both in vitro and in vivo [7–10], thus making it a very promising
candidate for future cancer therapy. TRAIL induces apoptosis by
binding to its cognate death domain-containing receptors (DR) 4
and 5 on the cell surface [11,12], which then leads to a cascade of
death-inducing signaling complex (DISC) formation, caspase
activation and ultimately the execution of the apoptotic program
[13–15]. We and others have previously shown that stem cell-
based delivery of S-TRAIL is highly efficacious in orthotopic brain
tumor models due to the tumoritropic properties of SC that lead to
on-site, sustained release of therapeutic S-TRAIL [16–19].
However, tumor cells have varying response to TRAIL mediated
killing and understanding the molecular mechanisms involved in
TRAIL resistance in tumor cells becomes a pre-requisite for the
broader successful application of TRAIL based therapies in the
future. Recently, abnormalities in c-Met signaling have been
reported to correlate with drug resistance in patients with cancer
[20]. However, the molecular mechanism for the role of c-Met in
TRAIL resistance in brain tumors remains unknown.
In the present study, we first screened a panel of brain tumor
lines for their sensitivity to S-TRAIL. In an effort to develop anti-
brain tumor therapies that overcome TRAIL resistance, we
explored the interaction between c-Met and DRs and their
contribution in TRAIL resistance in brain tumors. Furthermore,
we addressed the effect of targeting c-Met by lentivirial-mediated
expression of shRNA in combination with mesenchymal stem cell
(MSC)-delivered a secretable form of TRAIL (S-TRAIL) in MSC-
tumor cell co-cultures in vitro and in vivo.
Materials and Methods
Cell culture and viral transduction
Medulloblastoma (MB) cell lines (UW426, R262, R300, DAOY,
UW473) from American Type Culture Collection (ATCC) [21]
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
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fetal calf serum (Valley Biomedical Inc. Winchester, VA), 1%
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 2% sodium
bicarbonate (GIBCO), 1% nonessential amino acids (Mediatech
Inc, Manassas, VA), and 1% sodium pyruvate (Cellgro, Manassas,
VA). Established human glioma lines (LN229, LN319, U138,
U373, U87, U251 and Gli36) and primary human glioma lines
(GBM4 and GBM8) were grown as previously described [18,22].
Murine mesenchymal stem cells (MSC) (kindly provided by Dr.
Darwin Prockop, University of Texas) were grown as previously
described [18]. Lentiviral (LV)-Fluc-mCherry (Fmc), LV-scram-
bled (scr), LV-shMet (kindly provided by Jeffrey Engelman,
Massachusetts General Hospital Cancer Center, Boston, MA)
constructs were packaged in 293T cells as described previously
[23]. UW473 cells were infected with LV-scr or LV-shMet, and
then selected with puromycin, cultured for 1,2 passages, and
infected again with LV-Fmc. The double infected cells were then
subjected to fluorescence activated cell sorting (FACS Aria Cell-
Sorting System, BD Biosciences) and UW473scr-Fmc and
UW473shMet-Fmc lines were created. MSC-GFP and MSC-S-
TRAIL cell lines were created through retroviral transduction as
described previously [24].
In vitro cell viability assay
Human 293T cells were transduced with lentiviral vector LV-S-
TRAIL [25] at an MOI of 1 and 36 hours later, a culture medium
and the cells were harvested. Proteins were isolated from harvested
cells, resolved by sodium sodium dodecyl sulfate-polycrylamide gel
electrophoresis (SDS-PAGE), and immunoblotted with anti-
TRAIL antibody (ProScience, Poway, CA). S-TRAL concentra-
tion in the conditioned culture medium was measured by ELISA
with the TRAIL Immunoassay Kit (Biosource International,
Camarillo, CA) according to the manufacturer’s protocol, using
recombinant human TRAIL expressed in Escherichia coli as a
standard. Tumor cells (0.5610
4/well) were seeded in 96-well
plates and incubated with varying concentrations (0,1000 ng/ml)
of S-TRAIL obtained from transduced 293T cells for 24 h. Cell
viability was measured by a quantitative luminescence assays using
an ATP-dependent luminescent reagent (CellTiter-Glo, Promega,
Madison, WI) according to the manufacturer’s instructions. Based
on our previously published screening of glioma cells to TRAIL
mediated apoptosis, we chose TRAIL sensitive and resistant
glioma lines [26]. TRAIL sensitivity and resistance was deter-
mined by treating different glioma cells with different concentra-
tions of S-TRAIL and glioma cell viability was determined 24 h
post-TRAIL treatment. For c-Met inhibition studies, tumor cells
were incubated with c-Met inhibitor PHA665752 (1 uM) (Selleck
Chemicals, Houston, TX) for 12 h before TRAIL treatment. All
experiments were performed in triplicates.
Western blotting and immunoprecipitation
Following treatment, MB cells were lysed with NP40 buffer
supplemented with a protease inhibitor mixture (Complete Mini
EDTA-free, Roche Applied Science, Indianapolis, IN) and
phosphatase inhibitors II/III (Sigma, St Louis, MO). 30 mgo f
harvested proteins from each lysate were resolved on 10% SDS-
PAGE, and immunoblotted with antibodies against DR5, DR4
(ProSci, Inc., Poway, CA), c-Met, caspase 8, cleaved caspase 3,
cleaved poly (ADP-ribose) polymerase (PARP), FLICE inhibitory
protein (FLIP) (Cell Signaling, Beverly, MA), or a-tubulin (Sigma);
and detected by chemiluminescence after incubation with HRP-
conjugated secondary antibodies (Santa Cruz). Quantification of
western blot signals was performed using Image J. The data was
normalized to a-tubulin expression. For immunoprecipitation,
whole cell lysates were pre-incubated with Protein G Resin
(GenScript, Piscataway, NJ) for 3 h at 4uC to exclude nonspecific
binding to Protein G-Sepharose. After centrifugation, supernatants
containing proteins were added with IgG (Santa Cruz) or
indicated antibodies, rotated over night at 4uC, and then added
with Protein G-Sepharose for 3 h. The immune complex was spun
down, washed, resuspended in SDS-gel sample buffer and boiled
at 100uC for 5 min. Immunoprecipitates were separated by SDS-
PAGE and immunoblotted with indicated antibodies.
MB cells and MSC co-culture experiments and cell
viability assays
For co-culture experiments, UW473scr-Fmc or UW473shMet-
Fmc cells were plated with varying numbers of MSC-GFP or
MSC-S-TRAIL (10:1 or 5:1) in a 96-well plate, incubated for
36 hours and then cell viability was measured by a quantitative
luminescence assays using an ATP-dependent luminescent reagent
(CellTiter-Glo, Promega), according to the manufacturer’s in-
structions.
Intracranial cell implantation and in vivo imaging
UW473scr-Fmc, UW473shMet-Fmc, MSC-GFP, and MSC-S-
TRAIL cells were harvested at 80%–90% confluence and
implanted in various combinations as the following experimental
groups: UW473scr-Fmc with MSC-GFP, UW473scr-Fmc with
MSC-S-TRAIL, UW473shMet-Fmc with MSC-GFP, UW473sh-
Met-Fmc with MSC-S-TRAIL. These combinations were im-
planted stereotactically into nude mice brains (3610
5 tumor cells/
mouse and 6610
4 MSCs/mouse) in the following co-ordinates:
2.2 mm lateral from bregma, 2.5 mm ventral from dura on the
cranial suture. Mice were imaged for Fluc activity on 1, 3 and 7
days after implantations as previously described [18]. All in vivo
procedures were approved by the Subcommittee on Research
Animal Care at Massachusetts General Hospital.
Tissue processing and immunohistochemistry
Mice were perfused by injecting ice-cold 4% paraformaldehyde
(PFA) directly into the heart and the brains were fixed in 4% PFA
and frozen sections were obtained for immunohistochemistry. For
cleaved caspase 3 staining, sections were incubated for 1 hour in a
blocking solution (0.3% BSA, 8% goat serum and 0.3% Triton-
X100) at room temperature, followed by incubation at 4uC
overnight with anti-cleaved caspase 3 antibody (Cell Signaling)
diluted in blocking solution. Sections were incubated in Alexa
Fluor 647 goat anti-rabbit secondary antibody (Invitrogen), and
visualized using confocal microscope (LSM Pascal, Zeiss). The
number of cleaved caspase 3 positive cells was calculated by
counting positive cells in randomly selected field of views under a
microscope (206).
Statistical analysis
Data were analyzed by Student’s t-test when comparing two
groups and by ANOVA when comparing more than two groups.
Data are expressed as mean 6 s.e.m., and differences were
considered significant at P,0.05.
Results
Knock down c-Met protein sensitizes resistant brain
tumor cells to TRAIL-induced apoptosis
In order to investigate the relationship between c-Met protein
and TRAIL resistance in brain tumor cells, we first tested a panel
of human medulloblastoma (MB) cell lines for their sensitivity to
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strated resistance to various concentrations of S-TRAIL ranging
from 100,1000 ng/ml, UW426 line exhibited most sensitivity to
these concentrations (Fig. 1A). PI/Annexin V dual staining
combined with flow cytometry analysis revealed that UW426 line
exhibited 3-fold increase in apoptotic (Annexin V positive) cell
population when treated with S-TRAIL for 12 h, whereas no
significant increase in the apoptotic population was found in
DAOY or UW473 lines (Figure S1). In both of the TRAIL-
resistant cell lines, UW473 and DAOY, c-Met protein expression
levels were significantly higher than that of TRAIL-sensitive line
UW426 (Fig. 1B). Therefore to further study the role of c-Met in
TRAIL-resistance of MB cells, we used two strategies to
manipulate c-Met protein and its related signaling pathways.
First, PHA665752, a potent and highly selective c-Met inhibitor,
was used to block c-Met activation in MB cells. Western blot
analysis showed PHA665752 inhibited HGF-induced c-Met
phosphorylation in a dose dependent manner (Fig. 1C). Both
TRAIL-resistant UW473 and DAOY lines treated with different
concentrations of S-TRAIL with or without the presence of
PHA665752 showed no change in cell viability (Fig. 1D). Second,
UW473 cell line was stably transfected with lentiviral (LV)
constructs expressing c-Met-specific shRNA (LV-shMet) or
scrambled control (LV-scr). As revealed by the immunoblot
analysis, the c-Met protein level was significantly decreased in
UW473 expressing shMet compared to the scrambled control
(Fig. 1E). Although knocking down c-Met protein has no effect on
the cell viability (Figure S2A), S-TRAIL treatment resulted in a
significant decrease in cell viability in UW473shMet cells as
compared to controls (Fig. 1F). We further examined c-Met
protein levels among both TRAIL resistant and TRAIL sensitive
GBM lines obtained from our previous screening [26]. We found
that c-Met expression level was significantly higher in TRAIL
resistant lines as compared with that of TRAIL sensitive lines
Figure 1. Knock down of c-Met protein sensitizes resistant medulloblastoma (MB) cells to S-TRAIL treatment. (A) MB cell viability
analysis showing the effect of varying concentrations of S-TRAIL treatment (24 h) on different MB cell lines. (B) Left, Western blot analysis of c-Met
and tubulin levels in indicated MB cell lines. Right, plot showing the statistic results of c-Met protein levels in the MB lines. (C) MB lines UW473 and
DAOY were pre-incubated with c-Met inhibitor (PHA665752) before treatment with HGF (25 ng/ml). Protein lysates were then immunoblotted for
phosphorylated (p-Met) or total c-Met. (D) Cell viability analysis showing the effect of S-TRAIL treatment on both DAOY and UW473 cells with (+)o r
without (2) the presence of PHA665752 (PHA). (E) Western blot analysis c-Met and tubulin levels in UW473 cells stable-infected with LV-scrambled
(UW473scr) or LV-shMet virus (UW473shMet). (F) Cell viability analysis showing the effect of S-TRAIL treatment (24 h) on UW473, UW473scr, or
UW473shMet respectively. * denotes P,0.05.
doi:10.1371/journal.pone.0095490.g001
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incubation with the c-Met inhibitor, PHA665752 again showed no
effect on TRAIL sensitivity, while knocking down c-Met protein
levels via stable expression of c-Met specific shRNA (shMet)
greatly potentiated TRAIL sensitivity (Fig. 2C). Taken together,
the above results showed that knock-down of c-Met protein level,
but not inhibition of c-Met activation, sensitized TRAIL-resistant
brain tumor cells to TRAIL treatment.
c-Met interacts with DR5 and affects DISC formation
upon TRAIL stimulation
We further explored the mechanism underlying the role of c-
Met protein in TRAIL-resistance of brain tumor cells. As the
UW473 line is fully resistant to TRAIL, we utilized this line for
further studies. Western blot analysis showed that UW473shMet
line had a stable knock-down of c-Met levels compared to
UW473scr or UW473 lines (Figure S3). Next, we examined the
protein levels of caspase 8, cleaved caspase 3 and cleaved poly
(ADP-ribose) polymerase (PARP) in both UW473scr and
UW473shMet cells upon S-TRAIL stimulation for varying
amounts of time (Fig. 3A). A time dependent activation of caspase
8, followed by the cleavage of both caspase 3 and PARP were seen
in UW473shMet cells but not in UW473scr cells. Since c-Met has
the potential to complex with and modulate DRs independent of
its classical tyrosine kinase driven second messenger responses
[27], further immunoblot analysis showed that there was no
significant change in the levels of DR5, DR4, caspase 8 and
FLICE-like inhibitory protein (FLIP) in UW473shMet, UW473
and UW473scr cells (Fig. 3B). However, a reciprocal immuno-
precipitation assay demonstrated an interaction of c-Met with
DR5 (Fig. 3C). This finding led us to explore whether
downregulation of c-Met alters DISC formation. Both UW473scr
and UW473shMet cells extracts with or without S-TRAIL
treatment for 2 h were subjected to immunoprecipitation with
anti-caspase 8 antibody, precipitated complexes and then analyzed
by western blot using antibodies against DR5 (the main DR
isoform found on MB cell membrane according to our FACS
analysis). The protein level of DR5 among the precipitated DISC
components was greatly increased in S-TRAIL treated UW473sh-
Met cells compared to UW473scr cells (Fig. 3D), indicating that
the DISC formation was more efficient in UW473shMet cells
upon S-TRAIL stimulation. These results suggest that c-Met
interacts with DR5 and affects DISC formation upon TRAIL
treatment.
Knock down of c-Met sensitizes TRAIL resistant brain
tumor cells to stem cell-delivered S-TRAIL
To investigate whether c-Met knock down can sensitize
brain tumor cells to TRAIL treatment in vivo,w ef i r s t
engineered in vivo imageable UW473scr and UW473shMet
cells by transducing them with LV-Fluc-mCherry (Fmc). A
direct correlation between Fluc signal and cell number was
seen within the ranges tested in both cell lines (Figure S2B).
Additionally, we used engineered MSC lines expressing either
S-TRAIL (MSC-S-TRAIL) or GFP (MSC) [24]. MSC or MSC-
S-TRAIL co-cultured with either UW473scr-Fmc or
UW473shMet-Fmc in different ratios and the viability of
UW473 cells was assessed by Fluc bioluminescence imaging. A
significant decrease in cell viability was seen when UW437sh-
Met-Fmc cells co-cultured with MSC-S-TRAIL compared
Figure 2. Knock down of c-Met protein sensitizes resistant glioma cells to S-TRAIL treatment. (A) Western blot analysis of c-Met and
tubulin levels in indicated glioma lines. (B) Plot showing the statistic results of c-Met protein levels in both TRAIL-resistant and TRAIL-sensitive glioma
lines. (C) LN229 cell line viability analysis showing the effect of S-TRAIL treatment (24 h and 72 h) on indicated groups. * P,0.05.
doi:10.1371/journal.pone.0095490.g002
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TRAIL) (Fig. 4A). Next, we implanted UW473scr-Fmc or
UW473shMet-Fmc cells and MSC expressing only GFP or S-
TRAIL and GFP intracranially in nude mice and then imaged
the tumor cell growth over time. Serial Fluc bioluminescence
imaging revealed a significant inhibition of tumor cell growth
in mice when treated with MSC-S-TRAIL in UW437shMet-
Fmc cells (Fig. 4B and C). Furthermore, a significantly
increased number of cleaved caspase 3 positive cell was
observed in brain sections obtained from the mice implanted
with UW473shMet-Fmc and MSC-S-TRAIL compared with
that of UW473scr-Fmc and MSC-S-TRAIL (Fig.4D), showing
the involvement of caspase-mediated apoptosis and further
confirming that knock down c-Met overcomes TRAIL-resis-
tance of brain tumor cells in vivo.T h e s ein vivo results further
confirmed that knock down of c-Met does overcome TRAIL-
resistance of brain tumor cells and provided evidence for the
involvement of caspase-mediated apoptosis in this process.
Taken altogether, the in vitro and in vivo r e s u l t si nt h i ss t u d y
support each other in the notion that knock down of c-Met
sensitizes TRAIL resistant brain tumor cells to MSC-S-TRAIL
treatment.
Discussion
In this study, we investigated the involvement of c-Met protein
in TRAIL resistance and further identified the interaction between
c-Met and DR5 in brain tumor cells. We show that down-
regulation of c-Met potentiates DISC formation, and sensitizes
TRAIL resistant brain tumor cells to TRAIL mediated apoptosis
both in vitro and in vivo.
Much of the research till date involving TRAIL signaling has
focused on its usage in cancer treatment; however, an increasing
number of publications are starting to report on the predominance
of TRAIL resistance in primary human tumor cells [10], which
require sensitization for the induction of TRAIL-based apoptosis.
Although, sensitization of cancer cells by treatment with chemo-
therapeutic drugs and irradiation has been shown to restore
TRAIL sensitivity in many TRAIL-resistant brain tumor cells
[28], none of the previous studies have explored the role of c-Met
down-regulation in sensitizing TRAIL resistant tumor cells to
TRAIL mediated apoptosis. Previous studies have also show that
Figure 3. c-Met interacts with DR5 and affects DISC formation upon S-TRAIL stimulation. (A) Western blot analysis of caspase 8, cleaved
(cl)-caspase 3, cleaved (cl)-PARP, and tubulin levels in UW473scr and UW473shMet cells upon S-TRAIL stimulation for indicated time periods. (B)
Western blot analysis showing DR5, DR4, caspase 8, FLIP, and tubulin levels in UW473, UW473scr and UW473shMet cells. (C) Upper panel, Western
blot analysis showing the DR5 levels in the immunoprecipitates of IgG, anti-c-Met, and anti-DR5 (5% of each input was also blotted for total DR5 as
control); Lower panel, Western blot analysis showing the c-Met levels in the immunoprecipitates of IgG, anti-DR5 and anti-c-Met (5% of each input
was also blotted for total c-Met as control). (D) Left panel, Western blot analysis showing DR5 levels in the immunoprecipitates of anti-caspase 8 from
UW473scr or UW473shMet cells with (+) or without (2) the presence of S-TRAIL stimulation (5% of each input was also blotted for total DR5 as
control). Right panel, plot showing the quantitative analysis of the immunoblots on the left. * denotes P,0.05.
doi:10.1371/journal.pone.0095490.g003
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carcinoma (PTC) cell death, most likely through inhibition of
abnormal c-Met activation and upregulation of DR5 [29]. As
mentioned earlier, c-Met inhibitors function by inhibiting abnor-
mal c-Met activation, as opposed to affecting c-Met protein levels,
which can be observed through a change in p-Met levels. In
contrast to the high expression levels of p-Met in PTC cells, the
basal p-Met protein levels were extremely low in the brain tumor
lines we tested, which suggests that c-Met protein itself,
independent of its activation, might play a role in TRAIL
resistance of brain tumor cells. We thus exerted our efforts to
elucidate the involvement of c-Met protein in the TRAIL-related
apoptosis pathway. In contrast to the previous studies which
suggest that the dysregulation of HGF/c-Met pathway may affect
TRAIL-sensitivity via upregulation of DR5 level [30], we found
that both the levels of DR4 and DR5 protein were unaltered after
knocking down c-Met in TRAIL-resistant brain tumor cells. In
addition, co-immunoprecipitation experiments reveal that c-Met
interacts with DR5 and affects DISC formation most likely
through the same mechanism implicated in the interaction of c-
Met with Fas receptor, which sequestered Fas receptor and
prevented its self-aggregation and its downstream apoptosis
execution, as previously reported [31,32]. Based on our results,
we hypothesize that the interaction between c-Met and
DR5 sequesters DR5 and prevents its self-aggregation and its
downstream apoptosis execution upon TRAIL stimulation. Knock
down of c-Met protein greatly augments TRAIL-induced cell
apoptosis by freeing DR5 from the complex. Hence, our results
suggest a new mechanism for c-Met mediated TRAIL resistance
and provide immense evidence for the utility of a mechanism
based combination therapy for targeting brain tumors.
The limited availability of non-invasive methods to monitor
multiple molecular events has been one of the main limitations in
testing the efficacy of various tumor therapy paradigms. In our
previous studies, we have shown that we can follow delivery of
NSC [23], MSC [18] and quantify tumor burden in vivo [23,25]
using non-invasive bioluminescence imaging. In the current
studies, we have labeled tumor cells and stem cells with bimodal
imaging markers (bioluminescent and fluorescent) expressed as a
single transcript, which allows for expanding the number of events
that can be visualized in real-time in vivo and efficiently applied
bioluminescence imaging to follow tumor cell fate in vivo. Although
the optical imaging methods utilized in this study are ideally suited
for pre-clinical studies, further studies validating this approach
incorporating clinical imaging modalities like MRI will ease the
translation of our approach into clinics.
In conclusion, our studies propose for the first time that c-Met
plays a role in TRAIL-resistance of brain tumors by interacting
with DR5 (without changing DR5 levels) and affecting DISC
formation and subsequently TRAIL-mediated apoptosis execution
Figure 4. Knock down of c-Met sensitizes resistant MB cells to stem cell-delivered S-TRAIL both in vitro and in vivo. (A) Cell viability
measured by Fluc signal showing the effects of MSC-derived S-TRAIL in the co-cultures of MSC or MSC-S-TRAIL with UW473scr-Fmc (UW473scr), or
UW473shMet-Fmc (UW473shMet) cells at various culturing ratios. (B) Left panel: Fluc bioluminescence imaging (BLI) on days 1, 3 and 7 of mice
intraparenchymally implanted with UW473scr or UW473shMet cells admixed with MSC-S-TRAIL. Representative images of mice for each group are
shown. Right panel, statistical analysis of Fluc bioluminescence activity observed in respective groups of mice represented on the left. (C) Plot
showing Fluc bioluminescence intensities (representative of in vivo tumor growth). (D) Left, the brain sections from the indicated groups
(UW473scr+MSC-S-TRAIL or UW473shMet+MSC-S-TRAIL) stained with cl-caspase 3 (blue) and imaged together with mCherry (red, represents tumor
cells) and GFP (green, represents MSC secreting S-TRAIL). Right panel, plot representing the number of calculated activated caspase 3 positive cellsi n
the corresponding samples on the left panel (scale bar = 20 mm). ** denotes P,0.01.
doi:10.1371/journal.pone.0095490.g004
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that c-Met itself, independent of its activation, is involved in this
mechanism of TRAIL-resistance. Even though further testing
needs to be performed to elucidate the intricacies of this
mechanism possibly through the utilization of additional c-met
inhibitors and other methods to target c-Met expression, we
believe that the current study has taken the first steps toward
shedding the light on a new mechanism of TRAIL resistance in
brain tumors.
Supporting Information
Figure S1 Induction of apoptosis by S-TRAIL treatment
in MB cell lines. Effects of S-TRAIL treatment on UW426,
DAOY and UW473 lines. Numbers in the respective quadrants
indicate the percentage of cells presents in this area. In UW426
cells, the Annexin V positive cell population was significantly
increased upon S-TRAIL treatment. * P,0.05, ** P,0.01.
(TIF)
Figure S2 Characterization of modified UW473 lines. (A)
Cell viability analysis showing the growth rate of both UW473scr-
Fmc and UW473shMet-Fmc cells. (B) Top, representative
fluorescent images of both UW473scr-Fmc and UW473shMet-
Fmc cells. Bottom, plots showing the Fluc intensities of modified
tumor cells with different cell numbers.
(TIF)
Figure S3 The c-Met protein levels in UW473 lines
stably transduced with LV-scrambled or LV-shMet.
Western blot analysis of c-Met and tubulin levels in UW473 cells
stably transduced with LV-scrambled (UW473scr) or LV-shMet
(UW473shMet).
(TIF)
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